Eesti - eesti - Ravimiamet

sanoswiss uab - anastrosool - õhukese polümeerikattega tablett - 1mg 30tk; 1mg 90tk; 1mg 300tk; 1mg 100tk; 1mg 60tk; 1mg 14tk; 1mg 500tk; 1mg 56tk; 1mg 20tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - anastrosool - õhukese polümeerikattega tablett - 1mg 120tk; 1mg 500tk; 1mg 50tk; 1mg 90tk; 1mg 20tk; 1mg 10tk; 1mg 28tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - anastrosool - õhukese polümeerikattega tablett - 1mg 98tk; 1mg 90tk; 1mg 28tk; 1mg 1tk; 1mg 56tk; 1mg 10tk; 1mg 300tk; 1mg 84tk; 1mg 20tk; 1mg 14tk

Eesti - eesti - Ravimiamet

sia elvim - anastrosool - õhukese polümeerikattega tablett - 1mg 28tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - anastrosool - õhukese polümeerikattega tablett - 1mg 14tk; 1mg 20tk; 1mg 30tk; 1mg 50tk; 1mg 98tk; 1mg 300tk; 1mg 100tk; 1mg 60tk

Eesti - eesti - Ravimiamet

ideal trade links uab - anastrosool - õhukese polümeerikattega tablett - 1mg 30tk

Eesti - eesti - Ravimiamet

laboratoires juvise pharmaceuticals - anastrosool - õhukese polümeerikattega tablett - 1mg 84tk; 1mg 28tk; 1mg 98tk; 1mg 300tk; 1mg 20tk; 1mg 30tk; 1mg 100tk

Eesti - eesti - Ravimiamet

grindeks as - anastrosool - õhukese polümeerikattega tablett - 1mg 300tk; 1mg 28tk; 1mg 98tk; 1mg 100tk; 1mg 84tk; 1mg 30tk; 1mg 50tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - rinnanäärmed - endokriinse ravi, anti-östrogeene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pre - või perimenopausal naiste kombineeritud ravi palbociclib tuleks koos luteiniseeriva hormooni vabastav hormoon (lhrh) agonist.

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - rinnanäärmed - antineoplastilised ained - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.